CN48 - Pilot evaluation of RCC4Nurses to enhance nursing education and practice in survivorship care of people with advanced renal cell carcinoma in Europe

Background

Having access to specialist nurses is essential to enhance person-centred care in advanced renal cell carcinoma (RCC). Training opportunities for unrestricted education in advanced RCC care are still limited, adversely impacting patient access to specialist nursing workforce in Europe. RCC4Nurses was co-designed with clinical experts and patient representatives to fill this education gap.

Methods

RCC4Nurses was piloted in English with registered nurses from across Europe. Parameters of feasibility, acceptability, fidelity and efficacy were evaluated, guided by the Kirkpatrick framework. The project aimed to involve 160 participants, requiring a minimum of 30 completers for feasibility evaluation. Participants completed questionnaires before and after attending RCC4Nurses, including a knowledge test, confidence in looking after patients, and questions on acceptability and impact.

Results

From November 2023 to March 2024, 90 registered nurses enrolled. Participants were female (97%) with a postgraduate degree (62%), and with a median 11.7 years of work experience. Participants originated from 9 countries, predominantly the UK (47%). As of May 2024, forty participants (44.4%) had completed the programme with two months remaining until end of data collection. RCC4Nurses was evaluated positively, with 93% of participants agreeing that it met their learning expectations and helped in their work. Almost 95% would recommend it to colleagues. Nine in 10 participants agreed course duration was about right. Post-course evaluation showed that participants felt more prepared to look after people with advanced RCC (pre-course: mean 5.7/10; post-course: mean 7.95/10), also indicating commitment to apply what they learnt to their work (mean 8.79/10).

Conclusions

RCC4nurses is feasible, acceptable and effective as a continuing professional development resource for European nurses to develop specialist knowledge in advanced RCC and enhance survivorship care. Content translations into Spanish, Greek and Turkish are being planned alongside functionality refinement.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University of Glasgow.

Funding

Pfizer.

Disclosure

G. Kotronoulas: Other, Institutional, Principal Investigator, Project funded by Pfizer: Pfizer. C. Díez de los Ríos de la Serna: Other, Institutional, Research Grant, Project funded by Pfizer: Pfizer. D. Kelly: Other, Institutional, Research Grant, Project funded by Pfizer: Pfizer. A. Drury: Other, Institutional, Research Grant, Project funded by Pfizer: Pfizer; Non-Financial Interests, Personal, Advisory Board: EONS. W.H. Oldenmenger: Other, Institutional, Research Grant, Project funded by Pfizer: Pfizer. C. Papadopoulou: Other, Institutional, Research Grant, Project funded by Pfizer: Pfizer. T. Wiseman: Other, Institutional, Research Grant, Project funded by Pfizer: Pfizer.